<DOC>
	<DOCNO>NCT00370071</DOCNO>
	<brief_summary>The purpose study determine study drug effective safe treatment Multiple Sclerosis ( MS ) patient Chinese origin .</brief_summary>
	<brief_title>Open Label Study Evaluate Effect , Safety Tolerability Betaferon Standard Dose 250Âµg Patients Chinese Origin With Multiple Sclerosis</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer HealthCare AG , Germany . Bayer HealthCare AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Chinese origin diagnosis Relapsing remit multiple sclerosis secondary progressive multiple sclerosis Any disease Multiple Sclerosis ( MS ) could better explain patient sign symptom HIV ( human immunodeficiency virus ) infection Hepatitis A Syphilis immunodeficiency rheumatic disease Sjogren syndrome heart disease severe depression pregnancy lactation condition interfere Magnetic Resonance Imaging ( MRI ) Gadolinium DTPA ( Gadovist , contrast agent ) allergy allergy human protein , paracetamol , acetaminophen ibuprofen intolerance participation trial</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>MS</keyword>
</DOC>